CATEGORY: SLEEP & RECOVERY
A weekly shot that mimics three gut hormones cut the breathing interruptions of obstructive sleep apnea by 43% to 61% at its two higher doses, against roughly 15% on placebo, in a pair of 80-week randomized trials covering 691 adults.1 The drug is retatrutide, an experimental cousin of semaglutide and tirzepatide that isn’t approved anywhere yet. Its route was the scale. People on the higher doses lost about a fifth of their body weight, and their breathing followed.
Breathing That Stopped Nearly Once a Minute
Everyone enrolled had moderate or severe sleep apnea, confirmed by an overnight sleep study, plus obesity or overweight. The first trial took 243 adults without diabetes. The second took 448 adults who also had type 2 diabetes. Their apnea was serious: on average their breathing stopped or went dangerously shallow 56 to 59 times an hour. That’s close to once a minute, all night, every night. Each person was dealt one of four assignments by a random draw nobody could see or influence: a weekly retatrutide injection at 4, 9 or 12 milligrams, or an identical-looking placebo. Everyone also got diet and activity counseling, and the sleep studies were repeated at week 80 to count what changed.1
Interruptions Fell by the Dozens Per Hour
In the trial without diabetes, the hourly interruption count dropped by 34 events at the 9-milligram dose and 32 at the top dose, versus 10 on placebo. In the diabetes trial it dropped by 25 events at both higher doses, versus 10. More than half of people on those doses in both trials cut their interruptions at least in half. Many ended the trial with their apnea essentially resolved or reduced to mild without daytime sleepiness: 45% to 54% in the first trial and about 42% to 44% in the second, compared with 10% to 13% on placebo.1 Scores measuring how badly sleep problems spilled into the day improved too. Body weight fell about 19% to 23% at the higher doses, which is the engine of the whole result: less tissue pressing on the throat and chest means an airway that stays open.
Still Experimental, and Never Raced Against the Mask
Retatrutide is still experimental, and Eli Lilly, its maker, funded and helped run both trials. A related two-hormone drug, tirzepatide, already carries US approval for sleep apnea in adults with obesity, so this result extends a path regulators have accepted rather than opening a new one. Side effects looked familiar for this drug family: diarrhea, nausea and constipation led the list, and in some groups roughly one person in twelve stopped treatment over an adverse event. What the trials can’t yet say is whether fewer interruptions become fewer heart attacks or strokes down the years, or how the shot stacks up against CPAP, the pressurized mask that remains standard care. Nobody here was randomized against a mask.
Key Takeaways
- The improvement came through weight loss of roughly a fifth of body weight, not a direct effect on the airway, and the drug remains unapproved.
- Roughly half of participants on the higher doses ended with their apnea resolved or mild without sleepiness; whether that translates into fewer heart problems over time wasn’t measured.
References
- Grunstein RR, Somers VK, Azarbarzin A, et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. N Engl J Med. 2026; DOI 10.1056/NEJMoa2611477. link